Adverum Biotechnologies a new buy at H.C. Wainwright on wet AMD gene therapy [Seeking Alpha]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Seeking Alpha
soroparvovec (lxo-vec), could become an alternative to the current standard of care, anti-vascular endothelial growth factor (anti-VEGF) injections. The firm has a $30 price target (~209% upside based on Tuesday's close). Analyst Matthew Caufield noted that wet AMD has a prevalence of ~1.5M patients in the U.S. with ~200,000 new cases annually. While these patients rely on anti-VEGF for treatment currently, they have to be given as often as every four to eight weeks, leading to chronic treatment burden and non-compliance. An interim analysis of 26-week phase 2 data found that patients given either dose of lxo-vec saw 90% and 94%, respectively, reductions in annualized anti-VEGF injections. Also, a phase 1 trial showed that one lxo-vec treatment led to aflibercept protein expression maintained through three years. "Ixo-vec utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette," according to
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
- Immune-Onc Therapeutics Announces Presentation of IO-202 Phase 1b Interim Data of Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress [Yahoo! Finance]Yahoo! Finance
- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $1,150.00 price target on the stock.MarketBeat
- Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial [Yahoo! Finance]Yahoo! Finance
- Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) [Yahoo! Finance]Yahoo! Finance
REGN
Earnings
- 5/2/24 - Beat
REGN
Sec Filings
- 5/14/24 - Form 144
- 5/6/24 - Form 4
- 5/3/24 - Form 4
- REGN's page on the SEC website